Back to Search
Start Over
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
- Source :
- Targeted oncology. 12(4)
- Publication Year :
- 2017
-
Abstract
- Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT)
- Subjects :
- 0301 basic medicine
Oncology
Male
Cancer Research
medicine.medical_specialty
Indoles
Lung Neoplasms
medicine.medical_treatment
Population
Adenocarcinoma of Lung
Docetaxel
Adenocarcinoma
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Double-Blind Method
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Pharmacology (medical)
education
Survival analysis
education.field_of_study
Chemotherapy
business.industry
Hazard ratio
Middle Aged
medicine.disease
Survival Analysis
Europe
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Nintedanib
Female
Taxoids
business
Progressive disease
medicine.drug
Subjects
Details
- ISSN :
- 1776260X
- Volume :
- 12
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Targeted oncology
- Accession number :
- edsair.doi.dedup.....853a5e0e48fa766ba75da66766b79955